Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Emily Rickard"'
Publikováno v:
Globalization and Health, Vol 19, Iss 1, Pp 1-42 (2023)
Abstract Background Self-regulation of payment disclosure by pharmaceutical industry trade groups is a major global approach to increasing transparency of financial relationships between drug companies and healthcare professionals and organisations.
Externí odkaz:
https://doaj.org/article/b4de023953e846f09d9881d7fa85f2e6
Autor:
Emily Rickard, Piotr Ozieranski
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0252551 (2021)
Our objective was to examine conflicts of interest between the UK's health-focused All-Party Parliamentary Groups (APPGs) and the pharmaceutical industry between 2012 and 2018. APPGs are informal cross-party groups revolving around a particular topic
Externí odkaz:
https://doaj.org/article/dbbf646cd9c045b6af3835f91237f684
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
Externí odkaz:
https://doaj.org/article/9c87eff4d46d475abaa8862840ef8c29
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0235021 (2020)
BackgroundMany patient organisations collaborate with drug companies, resulting in concerns about commercial agendas influencing patient advocacy. We contribute to an international body of knowledge on patient organisation-industry relations by consi
Externí odkaz:
https://doaj.org/article/a6381542c7c74e158748ecf7f6ed5918
Publikováno v:
BMJ Open. 13:e061591
ObjectivesTo examine the characteristics of pharmaceutical payments to healthcare and patient organisations in the four UK countries. Compare companies spending the most; types of organisations receiving payments and types of payments in the four cou
Publikováno v:
Sociology of Health & Illness; 44(1), pp 188-210 (2022)
We examined the minimum extent of dependency of UK patient organisations on pharmaceutical industry funding using drug company disclosure reports and patient organisation financial accounts from 2012 to 2016. We used linear regression to explain the
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
BMJ Open
BMJ Open
ObjectivesTo examine the under-reporting of pharmaceutical company payments to patient organisations by donors and recipients.DesignComparative descriptive analysis of payments disclosed on drug company and charity regulator websites.SettingUK.Partic
Publikováno v:
Rickard, E, Ozieranski, P & Mulinari, S 2019, ' Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK ', Health Policy, vol. 123, no. 12, pp. 1244-1250 . https://doi.org/10.1016/j.healthpol.2019.08.007
Patient organisations contribute to many areas of pharmaceutical policy. In developing their organisational capacity, many turn to financial support from pharmaceutical companies, which may create conflicts of interests. However, the transparency of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeed6c239176cb61ab5a33d3e2517e15
https://purehost.bath.ac.uk/ws/files/197745489/Manuscript_Final.pdf
https://purehost.bath.ac.uk/ws/files/197745489/Manuscript_Final.pdf
Publikováno v:
JAMA Network Open
JAMA Network Open; 2(6), pp 196253-196253 (2019)
JAMA Network Open; 2(6), pp 196253-196253 (2019)
Key Points Question How are drug company payments to health care organizations distributed in the UK health care system? Findings This cross-sectional study of the Disclosure UK database found that in 2015, 4028 health care organizations received US